[{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Essex Biotechnology | Panacea Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Beijing Tongren Hospital \/ Essex Biotechnology | Panacea Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Tongren Hospital \/ Essex Biotechnology | Panacea Technologies"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Grand Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Strip","sponsorNew":"Beijing Tongren Hospital \/ Grand Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Tongren Hospital \/ Grand Pharmaceutical"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Novell Pharmaceutical Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novell Pharmaceutical Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novell Pharmaceutical Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novell Pharmaceutical Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Veritaz Healthcare","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Veritaz Healthcare","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Veritaz Healthcare \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Veritaz Healthcare \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Tampere University","sponsor":"Center for Vaccine Development - Mali | University College London Hospitals | Tro Da Ltd, UK | Duke-NUS Graduate Medical School | Bill & Melinda Gates Foundation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FINLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase III","graph3":"Tampere University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tampere University \/ Center for Vaccine Development - Mali | University College London Hospitals | Tro Da Ltd, UK | Duke-NUS Graduate Medical School | Bill & Melinda Gates Foundation | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tampere University \/ Center for Vaccine Development - Mali | University College London Hospitals | Tro Da Ltd, UK | Duke-NUS Graduate Medical School | Bill & Melinda Gates Foundation | Pfizer Inc"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"World Health Organization | Centers for Disease Control and Prevention | Kwame Nkrumah University of Science and Technology | Barcelona Institute for Global Health | Papua New Guinea Institute of Medical Research | Ghana Health Service | Noguchi Memorial ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ World Health Organization | Centers for Disease Control and Prevention | Kwame Nkrumah University of Science and Technology | Barcelona Institute for Global Health | Papua New Guinea Institute of Medical Research | Ghana Health Service | Noguchi Memorial ","highestDevelopmentStatusID":"10","companyTruncated":"London School of Hygiene & Tropical Medicine \/ World Health Organization | Centers for Disease Control and Prevention | Kwame Nkrumah University of Science and Technology | Barcelona Institute for Global Health | Papua New Guinea Institute of Medical Research | Ghana Health Service | Noguchi Memorial "},{"orgOrder":0,"company":"University of Oxford","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Oxford \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Keyrus Biopharma | VEEDA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratoires Thea \/ Keyrus Biopharma | VEEDA","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Keyrus Biopharma | VEEDA"},{"orgOrder":0,"company":"Inserm","sponsor":"University of Liverpool | Cardiff University | University of Nottingham | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Assistance Publique \u2013 H\u00f4pitaux de P","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ University of Liverpool | Cardiff University | University of Nottingham | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Assistance Publique \u2013 H\u00f4pitaux de P","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ University of Liverpool | Cardiff University | University of Nottingham | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Assistance Publique \u2013 H\u00f4pitaux de P"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Waterbury Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Waterbury Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Waterbury Hospital"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Merck & Co"},{"orgOrder":0,"company":"Lundquist Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lundquist Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Undisclosed"},{"orgOrder":0,"company":"UC San Francisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UC San Francisco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UC San Francisco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UC San Francisco \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Metabolic Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"University of Florida \/ Metabolic Solutions","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ Metabolic Solutions"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ Pfizer Inc"},{"orgOrder":0,"company":"NICHD Global Network for Women's and Children's Health","sponsor":"University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Colorado, Denver | Institute of Nutrition of Central America and Panama | Uni","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase III","graph3":"NICHD Global Network for Women's and Children's Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NICHD Global Network for Women's and Children's Health \/ University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Colorado, Denver | Institute of Nutrition of Central America and Panama | Uni","highestDevelopmentStatusID":"10","companyTruncated":"NICHD Global Network for Women's and Children's Health \/ University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Colorado, Denver | Institute of Nutrition of Central America and Panama | Uni"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | Mercy Medical Center | Johns Hopkins University | University of Virginia | University of Alabama at Birmingham | Christiana Care Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Gansu Provincial Maternal and Child Health Care Hospital | Mercy Medical Center | Johns Hopkins University | University of Virginia | University of Alabama at Birmingham | Christiana Care Health Services","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Gansu Provincial Maternal and Child Health Care Hospital | Mercy Medical Center | Johns Hopkins University | University of Virginia | University of Alabama at Birmingham | Christiana Care Health Services"},{"orgOrder":0,"company":"Rutgers Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Christiana Care Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ Christiana Care Health Services","highestDevelopmentStatusID":"11","companyTruncated":"Thomas Jefferson University \/ Christiana Care Health Services"},{"orgOrder":0,"company":"Philadelphia Eye Associates","sponsor":"Merck & Co | Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Philadelphia Eye Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philadelphia Eye Associates \/ Merck & Co | Thomas Jefferson University","highestDevelopmentStatusID":"8","companyTruncated":"Philadelphia Eye Associates \/ Merck & Co | Thomas Jefferson University"},{"orgOrder":0,"company":"Seattle Children\u2019s Hospital","sponsor":"National Heart, Lung, and Blood Institute | Cystic Fibrosis Foundation | CF Therapeutics Development Network Coordinating Center","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Seattle Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seattle Children\u2019s Hospital \/ National Heart, Lung, and Blood Institute | Cystic Fibrosis Foundation | CF Therapeutics Development Network Coordinating Center","highestDevelopmentStatusID":"11","companyTruncated":"Seattle Children\u2019s Hospital \/ National Heart, Lung, and Blood Institute | Cystic Fibrosis Foundation | CF Therapeutics Development Network Coordinating Center"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"London School of Hygiene & Tropical Medicine | Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ London School of Hygiene & Tropical Medicine | Medicines for Malaria Venture","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ London School of Hygiene & Tropical Medicine | Medicines for Malaria Venture"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Lihir Medical Centre","sponsor":"Barcelona Institute for Global Health | National Department of Health of Papua New Guinea | World Health Organization | University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAPUA NEW GUINEA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Lihir Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Lihir Medical Centre \/ Barcelona Institute for Global Health | National Department of Health of Papua New Guinea | World Health Organization | University of Washington","highestDevelopmentStatusID":"11","companyTruncated":"Lihir Medical Centre \/ Barcelona Institute for Global Health | National Department of Health of Papua New Guinea | World Health Organization | University of Washington"},{"orgOrder":0,"company":"Lihir Medical Centre","sponsor":"Barcelona Institute for Global Health | National Department of Health of Papua New Guinea | World Health Organization | University of Masarykova | Harvard School of Public Health (HSPH)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAPUA NEW GUINEA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Lihir Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lihir Medical Centre \/ Barcelona Institute for Global Health | National Department of Health of Papua New Guinea | World Health Organization | University of Masarykova | Harvard School of Public Health (HSPH)","highestDevelopmentStatusID":"11","companyTruncated":"Lihir Medical Centre \/ Barcelona Institute for Global Health | National Department of Health of Papua New Guinea | World Health Organization | University of Masarykova | Harvard School of Public Health (HSPH)"},{"orgOrder":0,"company":"Lihir Medical Centre","sponsor":"Centre For International Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAPUA NEW GUINEA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Lihir Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lihir Medical Centre \/ Centre For International Health","highestDevelopmentStatusID":"11","companyTruncated":"Lihir Medical Centre \/ Centre For International Health"},{"orgOrder":0,"company":"Universidad de Antioquia","sponsor":"Colgate Palmolive","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"COLOMBIA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Universidad de Antioquia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universidad de Antioquia \/ Colgate Palmolive","highestDevelopmentStatusID":"1","companyTruncated":"Universidad de Antioquia \/ Colgate Palmolive"},{"orgOrder":0,"company":"Adapt Produtos Oftalmol\u00f3gicos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BRAZIL","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adapt Produtos Oftalmol\u00f3gicos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adapt Produtos Oftalmol\u00f3gicos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adapt Produtos Oftalmol\u00f3gicos \/ Undisclosed"},{"orgOrder":0,"company":"Dr Ian B Wilkinson","sponsor":"University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Dr Ian B Wilkinson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Dr Ian B Wilkinson \/ University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica","highestDevelopmentStatusID":"11","companyTruncated":"Dr Ian B Wilkinson \/ University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica"},{"orgOrder":0,"company":"Clinical Research Management","sponsor":"Bill & Melinda Gates Foundation | Duke University | University of Sierra Leone | Syneos Health | University of North Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clinical Research Management","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clinical Research Management \/ Bill & Melinda Gates Foundation | Duke University | University of Sierra Leone | Syneos Health | University of North Carolina","highestDevelopmentStatusID":"7","companyTruncated":"Clinical Research Management \/ Bill & Melinda Gates Foundation | Duke University | University of Sierra Leone | Syneos Health | University of North Carolina"},{"orgOrder":0,"company":"Kevin Winthrop","sponsor":"Patient-Centered Outcomes Research Institute | National Jewish Health | University of Texas Health Science Center at Tyler | University Health Network, Toronto | New York University | Medical University of South Carolina | Mayo Clinic | LSU Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kevin Winthrop","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kevin Winthrop \/ Patient-Centered Outcomes Research Institute | National Jewish Health | University of Texas Health Science Center at Tyler | University Health Network, Toronto | New York University | Medical University of South Carolina | Mayo Clinic | LSU Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Kevin Winthrop \/ Patient-Centered Outcomes Research Institute | National Jewish Health | University of Texas Health Science Center at Tyler | University Health Network, Toronto | New York University | Medical University of South Carolina | Mayo Clinic | LSU Health Science"},{"orgOrder":0,"company":"World Health Organization","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh | Center for Public Health Kinetics | Kenya Medical Research Institute | University of Washington | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | University of Liverpool | Ce","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ International Centre for Diarrhoeal Disease Research, Bangladesh | Center for Public Health Kinetics | Kenya Medical Research Institute | University of Washington | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | University of Liverpool | Ce","highestDevelopmentStatusID":"10","companyTruncated":"World Health Organization \/ International Centre for Diarrhoeal Disease Research, Bangladesh | Center for Public Health Kinetics | Kenya Medical Research Institute | University of Washington | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | University of Liverpool | Ce"},{"orgOrder":0,"company":"Thomas M. Lietman","sponsor":"Bill & Melinda Gates Foundation | Pfizer Inc | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thomas M. Lietman","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas M. Lietman \/ Bill & Melinda Gates Foundation | Pfizer Inc | Stanford University","highestDevelopmentStatusID":"10","companyTruncated":"Thomas M. Lietman \/ Bill & Melinda Gates Foundation | Pfizer Inc | Stanford University"},{"orgOrder":0,"company":"Wim Janssens","sponsor":"Pro-Active Medical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Wim Janssens","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wim Janssens \/ Pro-Active Medical","highestDevelopmentStatusID":"10","companyTruncated":"Wim Janssens \/ Pro-Active Medical"},{"orgOrder":0,"company":"Manimarane Arjunan, MD,DM (Cardiology)","sponsor":"UR Anoop Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manimarane Arjunan, MD,DM (Cardiology)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group","highestDevelopmentStatusID":"1","companyTruncated":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group"},{"orgOrder":0,"company":"Translational Genomics Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atovaquone","moa":"||Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Translational Genomics Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Genomics Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Translational Genomics Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Nitric Oxide","moa":"||Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ECUADOR","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"||Steroid 5-alpha-reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometria Institute \/ Applied Biology"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The AIDS Clinical Trials Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The AIDS Clinical Trials Group \/ Undisclosed"},{"orgOrder":0,"company":"Progenabiome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenabiome \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ Undisclosed"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Knott Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series D Financing","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"ILiAD Biotechnologies \/ Knott Partners","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Knott Partners"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Vienna \/ Viravaxx"}]
Find Clinical Drug Pipeline Developments & Deals for Z-Pak (Azithromycin)
Details :
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Details :
Zoliflodacin, an antibiotic, is currently undergoing evaluation in late-stage clinical trials with patients for treating gonorrhea, in combination with ceftriaxone/azithromycin.
Details :
Azithromycin has antibacterial action as it binds to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.
Sponsor :
University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica
Details :
Azithromycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Sponsor :
University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica
Details :
Azithromycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Crohn Disease.
Details :
BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) :
Bordetella Pertussis Vaccine, Live Attenuated,Azithromycin,Undisclosed
Details :
Currently, the company caters to anti-infective and pain-management therapeutic areas and has a pipeline of products to enter into the cardio/diabetic and ortho/gynaecology segments, including Veriaz.
Details :
Azithromycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Tract Infections.
Details :
The funding will support a clinical trial to determine whether high doses of inhaled nitric oxide are safe and effective when used in conjunction with current standard-of-care therapies, including amikacin and azithromycin.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
